Systematic review: the use of somatostatin or octreotide in refractory diarrhoea.
BACKGROUND
Somatostatin and octreotide have multiple effects which make them ideal for treating diarrhoea of different aetiologies. Their use in a variety of conditions with refractory diarrhoea, however, is based on a limited number of studies.


OBJECTIVE
We undertook a systematic review of the available English literature to maximize an evidence-based approach to the treatment of refractory diarrhoea. We tested the hypothesis that efficacy is independent of aetiology.


RESULTS
A Medline and individual article search from 1965 to 2000 was undertaken on the use of somatostatin and octreotide in diarrhoea. All reports containing at least five subjects were included. The percentage response in case series and randomized controlled trials was compared, and a meta-analysis of randomized controlled trials where patient level data were provided was carried out. There were 30 publications found (18 case series, 12 randomized controlled trials). The response percentage was 73% overall in case series and 64% in randomized controlled trials (not significant). A meta-analysis of nine randomized controlled trials revealed significant heterogeneity despite an overall relative risk of 0.5 (95% confidence interval, 0.27-0.91). Subgroup analysis of the largest aetiological groups showed that acquired immunodeficiency syndrome studies were homogeneous, but somatostatin and octreotide were less effective. Post-chemotherapy studies remained heterogeneous and somatostatin and octreotide were highly effective.


CONCLUSIONS
While this review strengthens the consensus guidelines on the use of somatostatin and octreotide for refractory diarrhoea, evidence-based support requires additional studies.
Szilagyi
A
A
Department of Medicine, Division of Gastroenterology, The Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada. jrivard@gas.jgh.mcgill.ca
Shrier
I
I
D000930:Antidiarrheals / Q000627:therapeutic use*; D016022:Case-Control Studies; D003967:Diarrhea / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D016239:MEDLINE; D015201:Meta-Analysis as Topic; D015282:Octreotide / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013004:Somatostatin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000930:Antidiarrheals; D013004:Somatostatin; D015282:Octreotide